---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-025596"
form_type: "8-K"
ticker: null
cik: "0001779020"
company_name: "Danimer Scientific, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:34:18.911749+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Danimer Scientific raises $15M in registered direct offering of common stock and warrants

## Summary
- Gross proceeds of $15.0M from sale of 15M shares/equivalents and 15M warrants at $1.00 per unit.
- 11.25M common shares and 3.75M pre-funded warrants sold; common warrants have $1.33 strike, exercisable in 6 months.
- Net proceeds to be used for working capital and general corporate purposes.
- Roth Capital Partners acted as exclusive placement agent; 7% cash fee paid.
- Company and insiders subject to 90-day lock-up on securities sales.

## SEC filing metadata
- accession: 0001213900-24-025596
- form_type: 8-K
- cik: 0001779020
- company_name: Danimer Scientific, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/0001213900-24-025596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/ea020246801-8k_danimer.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-025596
- JSON: https://secwatch.observer/filing/0001213900-24-025596.json
- Plain text: https://secwatch.observer/filing/0001213900-24-025596.txt

## Key facts
- Material Agreements
  Danimer Scientific, Inc. entered into Purchase Agreement with a certain investor valued at aggregate of 11,250,000 shares of Class A common stock, pre-funded warrants for up to 3,750,000 shar (effective 2024-03-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a certain investor
  - Value: aggregate of 11,250,000 shares of Class A common stock, pre-funded warrants for up to 3,750,000 shar
  - Effective: 2024-03-20
  source text: On March 20, 2024, Danimer Scientific, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a certain investor for the purchase and sale, in a registered direct offering by the Company (the “Registered Offering”), of (i) an aggregate of 11,250,000 shares of its Class A common stock, par value $0.0001 per share (“Common Stock”) (ii) pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”) and (iii) accompanying warrants to purchase up to an aggregate of 15,000,000 shares of Common Stock (the “Common Warrants”) at a combined offering price of $1.00 per share of Common Stock and associated Common Warrant, or $0.9999 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/0001213900-24-025596-index.htm
- Material Agreements
  Danimer Scientific, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at cash fee of 7% of the aggregate gross proceeds raised in the Registered Offering, plus reimbursement (effective 2024-03-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Roth Capital Partners, LLC
  - Value: cash fee of 7% of the aggregate gross proceeds raised in the Registered Offering, plus reimbursement
  - Effective: 2024-03-20
  source text: On March 20, 2024, Danimer Scientific, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a certain investor for the purchase and sale, in a registered direct offering by the Company (the “Registered Offering”), of (i) an aggregate of 11,250,000 shares of its Class A common stock, par value $0.0001 per share (“Common Stock”) (ii) pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”) and (iii) accompanying warrants to purchase up to an aggregate of 15,000,000 shares of Common Stock (the “Common Warrants”) at a combined offering price of $1.00 per share of Common Stock and associated Common Warrant, or $0.9999 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/0001213900-24-025596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.